A Health Care Giant's Financial Health is on the Rise
There's good news for a health care giant in America. The company has shared its fourth-quarter earnings and revenue, and the numbers have exceeded expectations. The organization has also reconfirmed its profit forecast for 2026, showing that its recovery plan is right on track.
"The year before last was a challenging one, but last year we managed to steady the ship," says the company's Chief Financial Officer.
Financial Forecast
The company, which runs one of America's largest pharmacy chains, predicts a full-year profit of between $7 to $7.20 per share. This falls in line with the $7.17 per share that financial analysts were predicting. The CFO also mentioned that the company is sticking with its 2026 revenue forecast of at least $400 billion. It's not clear if these predictions consider all the obstacles the CFO mentioned.
The CFO explained that this forecast includes $20 billion in obstacles. About half of this is due to the company's decision to withdraw from the individual exchange market under the Affordable Care Act this year. The rest of the challenges come from adjusting to lower drug prices in the company's retail business after recent deals struck with over a dozen pharmaceutical companies.
Discounts and Lower Costs
Just last week, the company announced that its nearly 9,000 pharmacies are now accepting discount cards from a newly launched direct-to-consumer platform. The CFO said the company shares the goal of reducing costs with the administration. He added that these lower prices provide a new starting point for further cost negotiations, and they don't see this as a negative.
Business Growth
The company has said that this year's growth will be driven by the return to target margins at its recovering insurance business, and also by its pharmacy benefit manager. The CFO revealed that a primary-care provider is "improving its profitability" this year. This follows the company's decision to close 16 underperforming locations. For the retail pharmacy business, the CFO mentioned several positive factors, such as new technology investments and new locations and customers acquired from a company that filed for bankruptcy last year.
Positive Investor Response
Investors were pleased with the company's performance last year, with the stock price seeing a roughly 40% increase. This was after the CEO, who took the reins late the year before last, led a major restructuring to reverse years of underperformance. The company has reduced costs, reorganized leadership, and pulled out of weaker markets, which helped fuel the rise in stock price.
Fourth-Quarter Report
The company reported earnings per share of $1.09, adjusted versus 99 cents expected. The revenue was $105.69 billion versus $103.59 billion expected. The company posted a net income of $2.92 billion, or $2.30 per share, for the fourth quarter. This compares with a net income of $1.62 billion, or $1.30 per share, for the same period a year ago.
The company reported sales of $105.69 billion for the fourth quarter, up 8.2% from the same period a year ago. All three of its business segments showed growth. The insurance business brought in $36.29 billion in revenue during the quarter, up more than 10% from the fourth quarter of the year before last.
Looking Ahead
The CFO expects another year of margin improvement, primarily driven by privately run Medicare plans. The company's business for these plans is "continuing the path towards target margins" of 3% to 4% by 2028, he said.
The insurance segment's medical benefit ratio — a measure of total medical expenses paid relative to premiums collected — remained consistent from the prior year, at 94.8%. A lower ratio typically indicates that a company collected more in premiums than it paid out in benefits, resulting in higher profitability.
Other Business Segments
The company's pharmacy and consumer wellness division posted $37.66 billion in sales for the fourth quarter, up 12.4% from the same period a year earlier. It was partly due to higher prescription volume, but was offset by pharmacy reimbursement pressure and the impact of some generic drugs entering the market.
The company's health services segment generated $51.24 billion in revenue for the quarter, up 9% compared with the same quarter the year before last. This includes a division that negotiates drug discounts with manufacturers on behalf of insurance plans, creates lists of medications that are covered by insurance, and reimburses pharmacies for prescriptions.